Bristol Myers Squibb (NYSE:BMY) Stock Price Breaks Above 50 Day Moving Average on Analyst Downgrade

03 Nov 2026, 05:21 by Danessa Lincoln · The Markets Daily

Bristol Myers Squibb Company (NYSE:BMY – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Monday after The Goldman Sachs Group upgraded the stock from a hold rating to a strong-buy rating. The stock has a fifty day moving average of $62.71 and traded as high as $63.14. Bristol Myers Squibb shares last traded at $62.95, with a volume of 10,825,078 shares traded.

A number of other brokerages have also recently weighed in on BMY. UBS Group cut Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 5th. Wells Fargo & Company decreased their target price on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating on the stock in a research note on Tuesday, October 13th. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. JPMorgan Chase & Co. raised their target price on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $65.46.

View Our Latest Stock Analysis on Bristol Myers Squibb

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.05% of the stock is currently owned by company insiders.

Institutional Trading of Bristol Myers Squibb

Several hedge funds have recently modified their holdings of the stock. Alta Advisers Ltd raised its holdings in shares of Bristol Myers Squibb by 91.2% in the 3rd quarter. Alta Advisers Ltd now owns 14,817 shares of the biopharmaceutical company’s stock valued at $925,000 after purchasing an additional 7,067 shares in the last quarter. Syverson Strege & Co lifted its position in shares of Bristol Myers Squibb by 30.2% during the 3rd quarter. Syverson Strege & Co now owns 11,687 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 2,709 shares during the last quarter. Ullmann Wealth Partners Group LLC acquired a new position in shares of Bristol Myers Squibb during the third quarter worth $215,000. Westside Investment Management Inc. grew its stake in shares of Bristol Myers Squibb by 6.6% during the third quarter. Westside Investment Management Inc. now owns 7,341 shares of the biopharmaceutical company’s stock worth $457,000 after purchasing an additional 457 shares in the last quarter. Finally, Kestra Advisory Services LLC increased its holdings in Bristol Myers Squibb by 13.5% in the third quarter. Kestra Advisory Services LLC now owns 260,476 shares of the biopharmaceutical company’s stock valued at $16,254,000 after buying an additional 30,977 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Up 0.8%

The stock has a market cap of $128.59 billion, a PE ratio of 13.96, a price-to-earnings-growth ratio of 0.31 and a beta of 0.19. The firm has a fifty day moving average of $62.71 and a 200 day moving average of $59.97. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. The company had revenue of $13.07 billion for the quarter, compared to analysts’ expectations of $12.72 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. Bristol Myers Squibb’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period last year, the firm earned $1.63 earnings per share. On average, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.40 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.88%.

About Bristol Myers Squibb

(Get Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.